The global cancer biologics market was valued at USD 94.5 billion in 2022 and is projected to witness steady growth, expanding at a CAGR of 7.7% from 2023 to 2031. Driven by the rising prevalence of cancer, increasing adoption of targeted therapies, and advancements in biotechnology, the market is expected to surpass USD 185.0 billion by the end of 2031. Growing investments in research and development, along with the introduction of innovative biologic drugs, are further supporting market expansion worldwide.
Rise in prevalence of cancer, advancements in cancer biotechnology, increase in demand for targeted therapies, and favorable reimbursement policies are the major factors driving the global cancer biologics market. Cancer continues to be a significant health challenge globally, with 10 million fatalities in 2020. Surge in need for effective and innovative treatments of cancer is propelling the cancer biologics market growth. Furthermore, advancements in understanding cancer biology, identifying specific molecular targets, and developing biologic drugs that can selectively target and inhibit cancer cells are expected to accelerate market expansion.
Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85626
Rise in demand for targeted therapies, as these offer improved treatment outcomes and reduced side effects compared to traditional chemotherapy, offers lucrative opportunities to market players. Moreover, favorable reimbursement policies by governments and insurance providers have encouraged the adoption of cancer biologics, ensuring wider patient access to these advanced treatments.
Key Findings of the Market Report
- Based on drug class, Monoclonal Antibodies remain the revenue leader, while Cancer Growth Inhibitors are projected to record the highest growth rate during the forecast period.
- Lung Cancer and Breast Cancer remain the leading application segments, with lung cancer expected to grow at the highest CAGR due to persistent global risk factors.
- Hospitals dominate the end-use segment (approx. 60% share), though specialized Cancer Centers are the fastest-growing delivery channel for complex biologics.
- The trend toward humanized and fully human antibodies is accelerating, aiming to reduce immunogenicity and improve patient outcomes.
Global Market: Growth Drivers
- Increasing Global Cancer Incidence: A predicted 77% increase in new cases by 2050 is creating a massive long-term requirement for advanced therapeutic intervention.
- Expansion of Immuno-Oncology: The success of PD-1/PD-L1 inhibitors is driving a wave of combination therapy trials to enhance clinical efficacy.
- Advancements in Genomics: Improved molecular profiling (NGS) allows for the creation of "tailored" biologics that precisely target patient-specific cancer pathways.
- Supportive Regulatory Frameworks: Faster FDA and EMA approval pathways for orphan drugs and breakthrough biologics are shortening the "lab-to-patient" timeline.
Global Market: Key Players
Industry leadership is consolidating through strategic M&A and licensing deals, with players focusing on securing specialized manufacturing capacities for complex molecules.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Pfizer Inc.
- Novartis AG
- Amgen Inc.
- Johnson & Johnson (Janssen)
- BioNTech SE
- AbbVie Inc.
Global Market: Segmentation
By Drug Class
- Monoclonal Antibodies (Naked, Bispecific, ADCs)
- Growth Inhibitors
- Vaccines and Toxoids
- Cell and Gene Therapy
- Blood and Blood Products
By Application (Cancer Type)
- Lung Cancer
- Breast Cancer
- Hematological Malignancies (Blood Cancer)
- Colorectal Cancer
- Stomach & Liver Cancer
By End-Use
- Hospitals & Specialty Clinics
- Cancer Research Centers
- Academic & Research Institutes
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=85626<ype=S
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
